3-(1H-imidazol-1-yl)propanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	2794718
CHEMBL ID	20724
CHEBI ID	156055
SCHEMBL ID	2001103

Synonyms (38)

Synonym
HMS1696K09
EN300-26163
BB 0219203
3-imidazol-1-yl-propionic acid
1h-imidazole-1-propanoic acid
18999-45-6
EC-000.1978
STK392438
3-(1h-imidazol-1-yl)propanoic acid ,
CHEMBL20724 ,
AKOS000263943
CHEBI:156055
3-imidazol-1-ylpropanoic acid
FT-0691080
A4192
3-(1h-imidazol-1-yl)propanoic acid;3-(1-imidazolyl)propanoic acid
3-imidazol-1-yl-propionicacid
BBL012376
PS-3735
AB12684
SCHEMBL2001103
3(1h-imidazol-1-yl)propanoic acid
3-(imidazol-1-yl)-propionic acid
VSFNAZLYGOOSEY-UHFFFAOYSA-N
3-(1-imidazolyl)propionic acid
3-(1-imidazolyl)propanoic acid
mfcd02731119
SY024292
AC-26473
DTXSID80383348
3-imidazol-1-yl-propionic acid, aldrichcpr
CS-W002976
bdbm50026405
Z53111117
J-012268
BCP11410
3-chloro-2,2,3-trimethylbutane
3-(1-imidazolyl)propanoicacid

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

Role	Description
human urinary metabolite	Any metabolite (endogenous or exogenous) found in human urine samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

Class	Description
imidazolyl carboxylic acid	Any member of the class of imidazoles in which the imidazole ring is substituted by one (or more) carboxy group(s).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium- and chloride-dependent GABA transporter 2	Mus musculus (house mouse)	IC50 (µMol)	501.1870	1.4125	5.2683	8.1283	AID595474
Sodium- and chloride-dependent GABA transporter 3	Mus musculus (house mouse)	IC50 (µMol)	25.7040	1.5488	3.6761	8.1283	AID595475
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID595482	Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT2	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595477	Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID94678	In vivo blood glucose was determined in obese, hyperglycemic, hyperinsulinemic, insulin-resistant KKAy mice after a dose of 500 mg/kg for 4 days	2001	Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8	Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
AID595475	Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595509	Selectivity ratio of pIC50 for mouse GAT3 topIC50 for mouse GAT1	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595474	Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595476	Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595483	Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT4	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.84 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.63 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
n-carbamoyl-beta-alanine N-carbamoyl-beta-alanine: RN given refers to parent cpd. N-carbamoyl-beta-alanine : A beta-alanine derivative that is propionic acid bearing a ureido group at position 3.	2	1	beta-alanine derivative	metabolite; mouse metabolite
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.06	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
5-aminovaleric acid 5-aminovaleric acid: from red fox anal secretion; RN given refers to parent cpd. 5-aminopentanoic acid : A delta-amino acid comprising pentanoic acid with an amino substituent at C-5; a methylene homologue of gamma-aminobutyric acid (GABA) that is a weak GABA agonist.	2.06	1	amino acid zwitterion; delta-amino acid; omega-amino fatty acid	human metabolite
beta-alanine [no description available]	2.06	1	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
gamma-guanidinobutyric acid gamma-guanidinobutyric acid: RN given refers to parent cpd. 4-guanidinobutyric acid : A monocarboxylic acid that is butanoic acid substituted by a guanidino group at position 4.. 4-guanidinobutanoate : A monocarboxylic acid anion that is the conjugate base of 4-guanidinobutanoic acid.. 4-guanidinobutanoic acid : The 4-guanidino derivative of butanoic acid.	2	1	guanidines; monocarboxylic acid; zwitterion	fungal metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.06	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
creatine [no description available]	2	1	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
glycine [no description available]	2.06	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycocyamine glycocyamine: RN given refers to parent cpd; structure. guanidinoacetate : A monocarboxylic acid anion that is the conjugate base of guanidinoacetic acid, obtained by deprotonation of the carboxy group.. guanidinoacetic acid : The N-amidino derivative of glycine.	2	1	guanidinoacetic acids; zwitterion	bacterial metabolite; human metabolite; mouse metabolite; nutraceutical; rat metabolite
histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.	2	1	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
omega-aminoenantic acid [no description available]	2.06	1	medium-chain fatty acid
guanidinopropionic acid guanidinopropionic acid: alters creatine metabolism; structure. 3-guanidinopropanoic acid : A guanidine compound bearing an N-(2-carboxyethyl) substituent. It is a creatine analogue that has been found to decreases plasma glucose levels	2	1	guanidines; zwitterion	hypoglycemic agent
guanidinoethane sulfonate [no description available]	2	1	guanidines; organosulfonic acid; zwitterion
5-imidazolepropionic acid 5-imidazolepropionic acid: competitive inhibitor of urocanase reaction which catalyzes conversion of urocanate into imidazolone propionate; structure. dihydrourocanic acid : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 3 has been replaced by an imidazol-4-yl group.	2.06	1	imidazoles; monocarboxylic acid
imidazoleacetic acid imidazoleacetic acid: RN given refers to cpd without specific location of acetic acid attachment identified; structure. imidazol-5-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-5-yl group.. imidazol-4-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-4-yl group.	2.43	2	imidazoles; monocarboxylic acid	metabolite; mouse metabolite
beta-guanidinobutyric acid beta-guanidinobutyric acid: creatine antagonist	2	1
4-guanidinobenzoate 4-guanidinobenzoate: RN given refers to parent cpd. 4-guanidinobenzoic acid : Benzoic acid substituted at the para position by a guanidino group.	2	1	benzoic acids; guanidines
5-benzimidazolecarboxylic acid 5-benzimidazolecarboxylic acid: structure in first source	2.06	1
imidazol-1-ylacetic acid imidazol-1-ylacetic acid : An imidazolyl carboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by an imidazol-1-yl group.	2.06	1	imidazolyl carboxylic acid	metabolite
urocanic acid Urocanic Acid: 4-Imidazoleacrylic acid.. urocanic acid : An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.. trans-urocanic acid : A urocanic acid in which the double bond of the carboxyethene moiety has E configuration.	2.06	1	urocanic acid	human metabolite
snap 5114 [no description available]	2.06	1

Condition	Relationship Strength	Studies
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

chemdatabank.com